The Teva Pharmaceuticals and Sanofi drug, duvakitug, showed statistically significant and clinically meaningful results in a Phase 2b study in ulcerative colitis and Crohn’s disease. The drug is part of an emerging class of therapies that target TL1A, a protein involved in signaling that drives inflammation.
The post Teva and Sanofi Mid-Stage Data Reveal Shows Best-in-Class Potential for IBD Drug appeared first on MedCity News.
